Topic: acute lymphoblastic leukemia
Just a week after Affimed decided to put its T cell engager for blood cancers on hold, the FDA has placed the program on full clinical hold.
Affimed has halted work on trials of its lead T cell engager AFM11 for blood cancers after a death and two life-threatening events.
Since launch, Allogene has gained a new CFO and raised another $120 million. Now, it is looking to raise up to $100 million in its IPO.
A drug that blocks heat shock protein 90 (HSP90) offer a new way of treating an aggressive form of leukemia.
The AACR conference featured data on promising new approaches to CAR-T treatments and stimulating cancer-killing immune cells.
Gilead and its $12 billion biotech buy Kite Pharma have teamed up with Pfizer to work on a Yescarta-utomilumab combo test in certain blood cancers.
Juno Therapeutics, which dumped its lead CAR-T program in March, has inked license agreements with Eli Lilly, OncoTracker and Fred Hutch.
Fred Hutchinson scientists have identified biomarkers associated with dangerous side effects possible in cancer patients treated with CAR-T cells.
The filing positions one of 2017’s star performers on European exchanges to start trading in the U.S. and fund a phase 3 pancreatic cancer trial.
Juno Therapeutics has halted development of its lead CAR-T therapy months after patient deaths hindered the odds of success.